References
- Boer-Dennert M de, de Wit R, Schmitz PIM, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76:1055-61
- Glaus A, Knipping C, Morant R, et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 2004;12:708-15
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2010. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [Last accessed 16 August 2010]
- Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47
- Fabi A, Barduagni M, Lauro S, et al. Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 2003;11:156-61
- Siddiqui MA, Scott LJ. Palonosetron. Drugs 2004;64:1125-32
- Aloxi injection (palonosetron hydrochloride) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc., 2009
- Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron. Cancer 2003;98: 2473-82
- Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a doseranging clinical study. Ann Oncol 2004;15:330-7
- Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7
- Aapro MS, Grunberg SM, Manikhas GM, et al. A Phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-9
- Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomised, comparative Phase III trial. Lancet Oncol 2009;10:115-24
- Weiner MG, Livshits A, Carozzoni C, et al. Derivation of malignancy status from ICD-9 codes. American Medical Informatics Association (AMIA) 2003 Symposium Proceedings: 1050
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
- Tonato M, Clark-Snow RA, Osoba D, et al. Emesis induced by low or minimal emetogenic risk chemotherapy. Support Care Cancer 2005;13:109-11
- Schwartzberg L, Szabo S, Gilmore J, et al. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderate or highly emetogenic chemotherapy (LEC/MEC/HEC). CMRO 2011;27:837-45
- Molassiotis A, Saunders MP, Valle J, et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 2008;16:201-8
- Pirri C, Katris P, Trotter J, et al. Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Canc 2010; Published online 3 September 2010
- Booth CM, Clemons M, Dranitsaris G, et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 2007;5:374-80
- Markman M. Progress in preventing chemotherapy-induced nausea and vomiting. Cleve Clin J Med 2002;69:609-17